<!DOCTYPE html>
<html lang="es">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>An√°lisis de Inversi√≥n: GSK PLC (GSK)</title>
    <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:wght@400;700&family=Inter:wght@300;400;500;600;700&family=JetBrains+Mono:wght@400;500&display=swap" rel="stylesheet">
    <style>
        :root {
            --primary: #1a1a2e;
            --secondary: #16213e;
            --accent: #e94560;
            --gold: #f4a940;
            --success: #00d26a;
            --warning: #ffc107;
            --danger: #dc3545;
            --pharma: #f97316;
            --text: #333;
            --text-light: #6c757d;
            --bg-light: #f8f9fa;
            --border: #dee2e6;
        }
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: 'Inter', sans-serif; color: var(--text); line-height: 1.6; }
        .container { max-width: 1200px; margin: 0 auto; padding: 0 2rem; }

        .cover {
            min-height: 100vh;
            background: linear-gradient(135deg, #c2410c 0%, #ea580c 50%, #f97316 100%);
            color: white; display: flex; flex-direction: column; justify-content: center;
            align-items: center; text-align: center; padding: 2rem;
        }
        .cover-content { position: relative; z-index: 1; }
        .company-logo {
            width: 120px; height: 120px;
            background: white;
            border-radius: 20px; display: flex; align-items: center; justify-content: center;
            margin: 0 auto 2rem; font-size: 3rem;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            color: var(--pharma);
        }
        .cover h1 { font-family: 'Playfair Display', serif; font-size: 4rem; margin-bottom: 0.5rem; }
        .cover .ticker { font-family: 'JetBrains Mono', monospace; font-size: 1.5rem; opacity: 0.8; margin-bottom: 2rem; }
        .cover .tagline { font-size: 1.25rem; opacity: 0.9; max-width: 600px; margin-bottom: 3rem; }

        .verdict-badge {
            display: inline-block; padding: 1rem 3rem; border-radius: 50px;
            font-size: 1.5rem; font-weight: 700; text-transform: uppercase;
            letter-spacing: 2px; margin-bottom: 2rem;
        }
        .verdict-aceptable { background: linear-gradient(135deg, var(--warning), #ff9800); color: #000; }

        .score-display { font-family: 'Playfair Display', serif; font-size: 6rem; font-weight: 700; }
        .score-label { font-size: 1rem; text-transform: uppercase; letter-spacing: 3px; opacity: 0.8; }
        .cover-meta { position: absolute; bottom: 2rem; font-size: 0.875rem; opacity: 0.6; }

        .section { padding: 4rem 0; border-bottom: 1px solid var(--border); }
        .section-dark { background: var(--bg-light); }
        .section-title { font-family: 'Playfair Display', serif; font-size: 2.5rem; color: var(--primary); margin-bottom: 0.5rem; }
        .section-subtitle { color: var(--text-light); font-size: 1.1rem; margin-bottom: 2rem; }
        .section-number { font-family: 'JetBrains Mono', monospace; font-size: 0.875rem; color: var(--accent); text-transform: uppercase; letter-spacing: 2px; margin-bottom: 0.5rem; }

        .simple-box {
            background: linear-gradient(135deg, var(--pharma) 0%, #ea580c 100%);
            color: white; padding: 3rem; border-radius: 20px; margin-bottom: 2rem;
        }
        .simple-box h3 { font-family: 'Playfair Display', serif; font-size: 1.75rem; margin-bottom: 1.5rem; }
        .simple-box p { font-size: 1.2rem; line-height: 1.8; }

        .analogy-box { background: white; padding: 2rem; border-radius: 15px; border-left: 4px solid var(--gold); margin-top: 2rem; }
        .analogy-box h4 { color: var(--primary); margin-bottom: 0.5rem; }
        .analogy-box p { color: var(--text); }

        .dashboard { display: grid; grid-template-columns: repeat(5, 1fr); gap: 1.5rem; margin-bottom: 2rem; }
        .score-card { background: white; border-radius: 15px; padding: 1.5rem; text-align: center; box-shadow: 0 4px 20px rgba(0,0,0,0.08); }
        .score-card .icon { width: 50px; height: 50px; border-radius: 12px; display: flex; align-items: center; justify-content: center; margin: 0 auto 1rem; font-size: 1.5rem; }
        .score-card .value { font-family: 'JetBrains Mono', monospace; font-size: 2rem; font-weight: 700; color: var(--primary); }
        .score-card .label { font-size: 0.875rem; color: var(--text-light); margin-top: 0.5rem; }
        .score-card .max { font-size: 0.75rem; color: var(--text-light); opacity: 0.6; }
        .pillar-1 .icon { background: #e3f2fd; color: #1976d2; }
        .pillar-2 .icon { background: #e8f5e9; color: #388e3c; }
        .pillar-3 .icon { background: #fff3e0; color: #f57c00; }
        .pillar-4 .icon { background: #f3e5f5; color: #7b1fa2; }
        .pillar-5 .icon { background: #fce4ec; color: #c2185b; }

        .total-score {
            background: linear-gradient(135deg, var(--pharma) 0%, #ea580c 100%);
            color: white; padding: 2rem; border-radius: 15px; text-align: center;
        }
        .total-score .value { font-family: 'Playfair Display', serif; font-size: 4rem; font-weight: 700; }
        .total-score .label { font-size: 1rem; opacity: 0.8; text-transform: uppercase; letter-spacing: 2px; }

        .data-grid { display: grid; grid-template-columns: repeat(3, 1fr); gap: 1.5rem; }
        .data-card { background: white; border-radius: 15px; padding: 1.5rem; box-shadow: 0 4px 20px rgba(0,0,0,0.08); }
        .data-card h4 { font-size: 0.875rem; color: var(--text-light); text-transform: uppercase; margin-bottom: 0.5rem; }
        .data-card .value { font-family: 'JetBrains Mono', monospace; font-size: 1.75rem; font-weight: 600; color: var(--primary); }
        .data-card .change { font-size: 0.875rem; margin-top: 0.25rem; }
        .change.positive { color: var(--success); }
        .change.negative { color: var(--danger); }
        .change.neutral { color: var(--text-light); }

        .styled-table { width: 100%; border-collapse: collapse; background: white; border-radius: 15px; overflow: hidden; box-shadow: 0 4px 20px rgba(0,0,0,0.08); }
        .styled-table th { background: var(--primary); color: white; padding: 1rem; text-align: left; font-weight: 600; }
        .styled-table td { padding: 1rem; border-bottom: 1px solid var(--border); }
        .styled-table tr:last-child td { border-bottom: none; }

        .flag-grid { display: grid; grid-template-columns: repeat(2, 1fr); gap: 1rem; }
        .flag-item { display: flex; align-items: flex-start; gap: 1rem; padding: 1rem; background: white; border-radius: 10px; border-left: 4px solid var(--danger); }
        .flag-item.warning { border-left-color: var(--warning); }
        .flag-item.ok { border-left-color: var(--success); }
        .flag-icon { font-size: 1.5rem; }
        .flag-content h4 { font-size: 0.95rem; color: var(--primary); margin-bottom: 0.25rem; }
        .flag-content p { font-size: 0.85rem; color: var(--text-light); }

        .scenario-cards { display: grid; grid-template-columns: repeat(3, 1fr); gap: 1.5rem; }
        .scenario-card { background: white; border-radius: 15px; padding: 2rem; text-align: center; box-shadow: 0 4px 20px rgba(0,0,0,0.08); }
        .scenario-card.bull { border-top: 4px solid var(--success); }
        .scenario-card.base { border-top: 4px solid var(--warning); }
        .scenario-card.bear { border-top: 4px solid var(--danger); }
        .scenario-card h4 { font-size: 1rem; color: var(--text-light); text-transform: uppercase; margin-bottom: 1rem; }
        .scenario-card .price { font-family: 'Playfair Display', serif; font-size: 2.5rem; font-weight: 700; color: var(--primary); }
        .scenario-card .return { font-size: 1.25rem; font-weight: 600; }
        .scenario-card .return.positive { color: var(--success); }
        .scenario-card .return.negative { color: var(--danger); }
        .scenario-card .probability { font-size: 0.875rem; color: var(--text-light); margin-top: 1rem; }

        .conclusion-box {
            background: linear-gradient(135deg, var(--pharma) 0%, #ea580c 100%);
            color: white; padding: 3rem; border-radius: 20px; text-align: center;
        }
        .conclusion-box h3 { font-family: 'Playfair Display', serif; font-size: 2rem; margin-bottom: 1.5rem; }
        .conclusion-box p { font-size: 1.1rem; opacity: 0.9; max-width: 800px; margin: 0 auto 2rem; line-height: 1.8; }
        .action-buttons { display: flex; gap: 1rem; justify-content: center; flex-wrap: wrap; }
        .action-btn { padding: 1rem 2rem; border-radius: 50px; font-weight: 600; text-transform: uppercase; letter-spacing: 1px; font-size: 0.875rem; }
        .action-btn.primary { background: var(--gold); color: var(--primary); }
        .action-btn.secondary { background: rgba(255,255,255,0.1); color: white; border: 1px solid rgba(255,255,255,0.3); }

        @media (max-width: 968px) { .dashboard, .data-grid { grid-template-columns: repeat(2, 1fr); } .scenario-cards, .flag-grid { grid-template-columns: 1fr; } }
    </style>
</head>
<body>
    <div class="cover">
        <div class="cover-content">
            <div class="company-logo">üíä</div>
            <h1>GSK PLC</h1>
            <div class="ticker">NYSE: GSK ¬∑ LSE: GSK</div>
            <p class="tagline">Pharma global - Especialidades, vacunas, HIV y oncolog√≠a</p>
            <div class="verdict-badge verdict-aceptable">‚ö†Ô∏è Aceptable - Value con Riesgos</div>
            <div class="score-display">62/100</div>
            <div class="score-label">Puntuaci√≥n de Inversi√≥n</div>
        </div>
        <div class="cover-meta">An√°lisis generado el 27 de Enero, 2026 ¬∑ Agente /analista ¬∑ FMA System</div>
    </div>

    <section class="section">
        <div class="container">
            <div class="section-number">Secci√≥n 01</div>
            <h2 class="section-title">Explicaci√≥n Simple</h2>

            <div class="simple-box">
                <h3>¬øQu√© hace GSK?</h3>
                <p>
                    GSK (antes GlaxoSmithKline) es una de las farmac√©uticas m√°s grandes del mundo.
                    Fabrica medicamentos para HIV (como Triumeq), tratamientos de c√°ncer, vacunas
                    (como Shingrix para herpes z√≥ster), y medicamentos respiratorios. Si has tomado
                    Advair para asma o te vacunaste contra la gripe, posiblemente fue de GSK.
                </p>
                <div class="analogy-box">
                    <h4>üè≠ Analog√≠a: La f√°brica de salud veterana</h4>
                    <p>
                        GSK es como una f√°brica centenaria que sigue produciendo productos esenciales.
                        No es la m√°s innovadora ni la de mayor crecimiento, pero genera cash flow
                        constante, paga dividendos, y est√° intentando modernizarse bajo nuevo liderazgo.
                    </p>
                </div>
            </div>
        </div>
    </section>

    <section class="section section-dark">
        <div class="container">
            <div class="section-number">Secci√≥n 02</div>
            <h2 class="section-title">Dashboard de Puntuaci√≥n</h2>
            <div class="dashboard">
                <div class="score-card pillar-1">
                    <div class="icon">üìä</div>
                    <div class="value">13</div>
                    <div class="max">/20</div>
                    <div class="label">Calidad del Negocio</div>
                </div>
                <div class="score-card pillar-2">
                    <div class="icon">üí∞</div>
                    <div class="value">14</div>
                    <div class="max">/20</div>
                    <div class="label">Fortaleza Financiera</div>
                </div>
                <div class="score-card pillar-3">
                    <div class="icon">üè∞</div>
                    <div class="value">11</div>
                    <div class="max">/20</div>
                    <div class="label">Ventaja Competitiva</div>
                </div>
                <div class="score-card pillar-4">
                    <div class="icon">üëî</div>
                    <div class="value">10</div>
                    <div class="max">/20</div>
                    <div class="label">Gesti√≥n</div>
                </div>
                <div class="score-card pillar-5">
                    <div class="icon">üíµ</div>
                    <div class="value">14</div>
                    <div class="max">/20</div>
                    <div class="label">Valoraci√≥n</div>
                </div>
            </div>
            <div class="total-score">
                <div class="value">62/100</div>
                <div class="label">Puntuaci√≥n Total ¬∑ Aceptable</div>
            </div>
        </div>
    </section>

    <section class="section">
        <div class="container">
            <div class="section-number">Secci√≥n 03</div>
            <h2 class="section-title">An√°lisis del Negocio</h2>
            <div class="data-grid">
                <div class="data-card">
                    <h4>Precio ADR (NYSE)</h4>
                    <div class="value">~$48-49</div>
                    <div class="change positive">+37% en 12 meses</div>
                </div>
                <div class="data-card">
                    <h4>P/E Ratio</h4>
                    <div class="value">~13.7x</div>
                    <div class="change positive">Barato vs peers</div>
                </div>
                <div class="data-card">
                    <h4>Dividend Yield</h4>
                    <div class="value">~3.4-3.5%</div>
                    <div class="change positive">64p/share 2025</div>
                </div>
                <div class="data-card">
                    <h4>2025 Guidance (raised)</h4>
                    <div class="value">Turnover +6-7%</div>
                    <div class="change positive">Core EPS +10-12%</div>
                </div>
                <div class="data-card">
                    <h4>Core Op. Margin</h4>
                    <div class="value">32.9%</div>
                    <div class="change positive">+180bps YoY</div>
                </div>
                <div class="data-card">
                    <h4>H1 2025 FCF</h4>
                    <div class="value">>¬£1.8B</div>
                    <div class="change positive">3x vs a√±o anterior</div>
                </div>
            </div>

            <div style="margin-top: 2rem;">
                <h3 style="color: var(--primary); margin-bottom: 1rem;">√Åreas Terap√©uticas Clave</h3>
                <table class="styled-table">
                    <thead>
                        <tr>
                            <th>√Årea</th>
                            <th>Productos Principales</th>
                            <th>Perspectiva</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>HIV</strong></td>
                            <td>Triumeq, Dovato, Cabenuva</td>
                            <td>‚ö†Ô∏è Dolutegravir patent expires 2028</td>
                        </tr>
                        <tr>
                            <td><strong>Oncolog√≠a</strong></td>
                            <td>Blenrep, Jemperli, Ojjaara</td>
                            <td>‚úÖ Creciendo r√°pido (comeback Blenrep)</td>
                        </tr>
                        <tr>
                            <td><strong>Vacunas</strong></td>
                            <td>Shingrix, Arexvy (RSV)</td>
                            <td>‚ö†Ô∏è Arexvy sales cayendo en US</td>
                        </tr>
                        <tr>
                            <td><strong>Respiratorio</strong></td>
                            <td>Trelegy Ellipta, Nucala</td>
                            <td>‚úÖ Estable</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>
    </section>

    <section class="section section-dark">
        <div class="container">
            <div class="section-number">Secci√≥n 04</div>
            <h2 class="section-title">Zantac: De Amenaza a Resoluci√≥n</h2>

            <div style="background: white; border-radius: 15px; padding: 2rem; box-shadow: 0 4px 20px rgba(0,0,0,0.08); border-left: 4px solid var(--success);">
                <h4 style="color: var(--primary); margin-bottom: 1rem;">‚úÖ Litigio Largamente Resuelto</h4>
                <ul style="color: var(--text-light); line-height: 2;">
                    <li><strong>Oct 2024:</strong> Settlement de $2.2B para ~80,000 casos (93% del exposure en cortes estatales)</li>
                    <li><strong>Jul 2025:</strong> Delaware Supreme Court falla a favor de GSK, excluyendo testimonios de expertos como cient√≠ficamente no confiables</li>
                    <li><strong>Carga contable:</strong> ~¬£1.8B, sin admisi√≥n de responsabilidad</li>
                    <li><strong>Consenso:</strong> "Riesgo manejable, no amenaza existencial"</li>
                </ul>
            </div>

            <div style="margin-top: 2rem; padding: 1.5rem; background: white; border-radius: 10px; border-left: 4px solid var(--warning);">
                <h4 style="color: var(--primary); margin-bottom: 0.5rem;">‚ö†Ô∏è Por qu√© esto importaba</h4>
                <p style="color: var(--text-light);">
                    Zantac era un anti√°cido popular que GSK vendi√≥ antes de que se vinculara con posible
                    carcinogenicidad. El miedo a miles de demandas multimillonarias deprimi√≥ la acci√≥n
                    durante a√±os. La resoluci√≥n favorable ha liberado el rally del 37% en 2025.
                </p>
            </div>
        </div>
    </section>

    <section class="section">
        <div class="container">
            <div class="section-number">Secci√≥n 05</div>
            <h2 class="section-title">Cambio de Liderazgo</h2>

            <div class="data-grid">
                <div class="data-card" style="border-left: 4px solid var(--pharma);">
                    <h4>CEO Saliente</h4>
                    <div class="value" style="font-size: 1.2rem;">Emma Walmsley</div>
                    <div class="change neutral">9 a√±os como CEO, deja Dic 2025</div>
                </div>
                <div class="data-card" style="border-left: 4px solid var(--success);">
                    <h4>Nuevo CEO</h4>
                    <div class="value" style="font-size: 1.2rem;">Luke Miels</div>
                    <div class="change positive">Ex-CCO, desde 1 Ene 2026</div>
                </div>
                <div class="data-card" style="border-left: 4px solid var(--gold);">
                    <h4>Target 2031</h4>
                    <div class="value" style="font-size: 1.2rem;">>¬£40B Revenue</div>
                    <div class="change neutral">vs ¬£34.8B Street consensus</div>
                </div>
            </div>

            <div style="margin-top: 2rem; padding: 1.5rem; background: white; border-radius: 10px;">
                <h4 style="color: var(--primary); margin-bottom: 1rem;">Capital Returns</h4>
                <ul style="color: var(--text-light); line-height: 2;">
                    <li><strong>Buyback:</strong> ¬£2B programa, >11.5M acciones recompradas desde Sep 2025</li>
                    <li><strong>Dividendo 2025:</strong> 64p/share (~3.4-3.5% yield)</li>
                    <li><strong>Buyback completion:</strong> H1 2026</li>
                </ul>
            </div>
        </div>
    </section>

    <section class="section section-dark">
        <div class="container">
            <div class="section-number">Secci√≥n 06</div>
            <h2 class="section-title">Checklist de Red Flags</h2>
            <div class="flag-grid">
                <div class="flag-item warning">
                    <div class="flag-icon">‚ö†Ô∏è</div>
                    <div class="flag-content">
                        <h4>Patent cliff: Dolutegravir (2028)</h4>
                        <p>Principal f√°rmaco HIV pierde exclusividad. Necesitan reemplazarlo</p>
                    </div>
                </div>
                <div class="flag-item warning">
                    <div class="flag-icon">‚ö†Ô∏è</div>
                    <div class="flag-content">
                        <h4>Arexvy (RSV) decepciona</h4>
                        <p>Ventas US cayeron tras cambio en recomendaciones de vacunaci√≥n</p>
                    </div>
                </div>
                <div class="flag-item warning">
                    <div class="flag-icon">‚ö†Ô∏è</div>
                    <div class="flag-content">
                        <h4>Citadel tiene short 0.5%</h4>
                        <p>Hedge fund esc√©ptico del pipeline a largo plazo</p>
                    </div>
                </div>
                <div class="flag-item warning">
                    <div class="flag-icon">‚ö†Ô∏è</div>
                    <div class="flag-content">
                        <h4>Gap management vs Street</h4>
                        <p>Target ¬£40B 2031 vs consensus ¬£34.8B (-15%)</p>
                    </div>
                </div>
                <div class="flag-item ok">
                    <div class="flag-icon">‚úÖ</div>
                    <div class="flag-content">
                        <h4>Zantac resuelto</h4>
                        <p>Riesgo legal que deprim√≠a acci√≥n est√° mayormente eliminado</p>
                    </div>
                </div>
                <div class="flag-item ok">
                    <div class="flag-icon">‚úÖ</div>
                    <div class="flag-content">
                        <h4>Guidance raised + FCF triplicado</h4>
                        <p>Mejora operativa real, no solo narrativa</p>
                    </div>
                </div>
                <div class="flag-item ok">
                    <div class="flag-icon">‚úÖ</div>
                    <div class="flag-content">
                        <h4>P/E 13.7x + 3.4% yield</h4>
                        <p>Valoraci√≥n atractiva para pharma grande</p>
                    </div>
                </div>
                <div class="flag-item ok">
                    <div class="flag-icon">‚úÖ</div>
                    <div class="flag-content">
                        <h4>Pipeline oncolog√≠a prometedor</h4>
                        <p>Blenrep comeback, Jemperli ramping, m√∫ltiples catalizadores</p>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <section class="section">
        <div class="container">
            <div class="section-number">Secci√≥n 07</div>
            <h2 class="section-title">Valoraci√≥n a 5 A√±os</h2>
            <div class="scenario-cards">
                <div class="scenario-card bull">
                    <h4>üöÄ Pipeline Delivers</h4>
                    <div class="price">$70+</div>
                    <div class="return positive">+43%</div>
                    <p style="color: var(--text-light); margin-top: 1rem; font-size: 0.9rem;">
                        Oncolog√≠a explota. Reemplazos HIV exitosos. ¬£40B+ revenue.
                        Multiple re-rating a 18x.
                    </p>
                    <div class="probability">Probabilidad: 25%</div>
                </div>
                <div class="scenario-card base">
                    <h4>üìä Crecimiento Modesto</h4>
                    <div class="price">$55</div>
                    <div class="return positive">+12%</div>
                    <p style="color: var(--text-light); margin-top: 1rem; font-size: 0.9rem;">
                        Cumple Street consensus. Patent cliff manejado.
                        Yield + buybacks dan retorno total ~15-18%.
                    </p>
                    <div class="probability">Probabilidad: 50%</div>
                </div>
                <div class="scenario-card bear">
                    <h4>üêª Pipeline Falla</h4>
                    <div class="price">$35</div>
                    <div class="return negative">-29%</div>
                    <p style="color: var(--text-light); margin-top: 1rem; font-size: 0.9rem;">
                        Oncolog√≠a decepciona. Dolutegravir cliff sin reemplazo.
                        Vacunas siguen cayendo. Value trap.
                    </p>
                    <div class="probability">Probabilidad: 25%</div>
                </div>
            </div>

            <div style="margin-top: 2rem; padding: 2rem; background: white; border-radius: 15px;">
                <h4 style="color: var(--primary); margin-bottom: 1rem;">üìä Valor Esperado: $53.75 (+10%)</h4>
                <p style="color: var(--text-light);">
                    El valor esperado es modestamente positivo. Sumando el dividendo de 3.4%, el retorno
                    total esperado anualizado es ~3-4%, m√°s o menos en l√≠nea con bonds de alta calidad.
                    Es una inversi√≥n defensiva, no de crecimiento agresivo.
                </p>
            </div>
        </div>
    </section>

    <section class="section section-dark">
        <div class="container">
            <div class="section-number">Secci√≥n 08</div>
            <h2 class="section-title">Conclusi√≥n</h2>

            <div class="conclusion-box">
                <h3>‚ö†Ô∏è ACEPTABLE - Value con Dividendo</h3>
                <p>
                    GSK es una farmac√©utica barata (P/E 13.7x) con yield del 3.4% y el riesgo Zantac
                    resuelto. El rally del 37% refleja la mejora, pero los retos siguen: patent cliff
                    en HIV (2028), vacunas decepcionantes, y gap entre targets del management y Street.
                    Para inversores que buscan income y exposici√≥n defensiva a pharma, con tolerancia
                    a volatilidad de pipeline. No es para growth investors.
                </p>
                <div class="action-buttons">
                    <span class="action-btn primary">HOLD si Ya Tienes</span>
                    <span class="action-btn secondary">Small Position OK (3-4%)</span>
                </div>
            </div>

            <div style="margin-top: 2rem;">
                <h3 style="color: var(--primary); margin-bottom: 1rem;">üìã Alertas</h3>
                <ul style="color: var(--text-light); line-height: 2;">
                    <li><strong>Watch:</strong> Progreso de pipeline oncolog√≠a (Blenrep, Jemperli)</li>
                    <li><strong>Catalizador:</strong> FDA decisions en varios programas 2026</li>
                    <li><strong>Risk:</strong> Dolutegravir replacement (pre-2028)</li>
                    <li><strong>Analyst consensus:</strong> Hold, target $44.13 (downside?)</li>
                </ul>
            </div>
        </div>
    </section>

    <footer style="background: var(--primary); color: white; padding: 2rem; text-align: center;">
        <p style="opacity: 0.8; font-size: 0.875rem;">An√°lisis generado por Agente /analista ¬∑ FMA System ¬∑ 27 Enero 2026</p>
    </footer>
</body>
</html>